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Objective: Cancer survivors commonly experience long-term anxiety and depression. Anxiety 
and depression might result from problems emerging during survivorship rather than illness 
and treatment. This study tested three potential causal paths: 1) concerns about physical 
symptoms and functional problems and fear of cancer recurrence (FCR) arising during 
survivorship directly cause anxiety and depression, 2) an indirect path whereby FCR mediates 
effects of concerns about physical symptoms and functional problems on anxiety and 
depression, and 3) a reciprocal path whereby anxiety and depression cause concerns about 
physical symptoms and functional problems and FCR, which exacerbate later anxiety and 
depression. Methods: Sample of 453 uveal melanoma survivors who completed observations 
6-, 12-, 24-, 36-, 48- and 60-months post-diagnosis and did not miss two consecutive 
observations. Cross-lagged analyses were conducted to predict Hospital Anxiety and 
Depression Scale subscale scores. Symptoms and functional problems were measured using 
the EORTC OPT 30 scale, and FCR operationalised by the EORTC OPT 30 worry about 
recurrence scale. Covariates were age, gender, treatment modality and visual acuity of the 
fellow eye and chromosome-3 status (which accurately predicts 10-year survival), worry and 
anxiety or depression. Results: All paths received some support, although the indirect path 
emerged only for anxiety in females. Concerns about physical symptoms, functional problems 
and FCR originated in survivorship and appeared to both influence and be influenced by 
anxiety and depression. Conclusions: Findings emphasise the importance of actively 
monitoring survivors to prevent, detect and intervene in the development of anxiety and 
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Between 15 and 26% of cancer survivors experience anxiety or depression two to five 
years after treatment,1-4 with anxiety and depression defined by structured interviews or 
clinically significant scores on measures of symptomatology. In addition to reducing quality of 
life,5 anxiety and depression reduce treatment engagement,6 medical recovery, satisfaction with 
health services7 and adjustment to life post-treatment.1,8 
 Research typically involves prospectively predicting anxiety and depression from 
theoretically-derived variables, measured at baselines established at initial diagnosis or 
cessation of primary medical treatment. Beyond temperamental variables, such as neuroticism, 
this research has produced little evidence that demographic, psychological, social or clinical 
factors reliably predict longer-term distress in cancer survivors.9 Cross-lagged studies in the 
mental health literature show that recent events, such as life experiences, predict anxiety and 
depression.10 Survivor studies rarely examine whether events occurring after treatment predict 
later anxiety and depression symptoms. Thus, events occurring during survivorship, such as 
worsening physical symptoms or functional problems, is overlooked.9 This paper examines 
these impacts in a prospective study of Uveal Melanoma (UM) survivors 
Concerns about Physical Symptoms, Functional Problems and Fear of Cancer 
Recurrence  
Survivors commonly experience physical symptoms that cause pain, discomfort, 
inconvenience or disfigurement. Further, physical symptoms can degrade functioning in 
routine life tasks.11 Concerns about physical symptoms and functional problems frequently 
emerge during cancer survivorship or persist long into it.12 Physical symptoms and functional 
problems increase vulnerability to anxiety and depression in multiple chronic illness 
populations,13 and are cross-sectionally associated with anxiety and depression in 
survivors.2,4,12,14 Further, many survivors are at risk of local and metastatic cancer recurrence. 
A large literature on the aetiology and effects of survivors’ fear of cancer recurrence (FCR) has 
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recently emerged.12,14 Both objective risk and FCR are cross-sectionally associated with 
anxiety.12,14   
Studies cited above suggest that physical symptoms, functional problems and FCR 
might cause anxiety and depression, but their cross-sectional designs provide weak evidence 
of causality. Understanding causal pathways is important for intervention development. In this 
study, we prospectively tested three feasible paths, each suggesting different prevention and 
treatment interventions.  
The first path is direct, whereby the strain of physical symptoms, functional problems 
and FCR cause anxiety and depression.2,4 The second path is indirect. Somatic phenomena, 
such as symptoms and functional problems, cause survivors to subjectively appraise their 
causes and implications.15 Symptoms that are similar to survivors’ initial cancer symptoms may 
be interpreted as recurrences, or simply activate traumatic memories of illness and treatment.16 
These appraisals may lead to FCR.15 Thus, FCR might mediate relationships between physical 
symptoms, functional problems and anxiety and depression. One prospective study shows 
evidence of mediation.17 However, this study was conducted over two years and cannot address 
longer-term outcomes experienced by survivors.2,4  
Third, paths may be reciprocal - survivors might experience downward spirals, 
whereby anxiety or depression cause deteriorations in actual or perceived physical symptoms, 
functional problems or FCR. This deterioration could aggravate the initial anxiety or 
depression. Anxiety and depression might increase concerns about physical symptoms or 
functional problems in three ways. They can cause biological changes (e.g., immune response 
changes),18 behavioural changes (e.g., reducing disease-modifying behaviours such as 
medication adherence),19 or simply amplify concerns about existing disease.20   
In this study, the three paths hypothesised above are examined in a population of 
patients with UM.  
Uveal Melanoma  
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UM mostly originates (90%) from the choroid of the eye and is generally treated by 
surgery or radiotherapy.21 UM is uniquely suited to investigations into problems of 
survivorship. First, physical symptoms and functional problems are mainly confined to 
survivorship. Pre-treatment symptoms, such as visual disturbances, can occur but are unlikely 
to be debilitating.22 Surgical and radiotherapy treatments can be experienced as difficult, but 
chemotherapy is rare. Thus, to survivors, post-treatment symptoms are often novel and 
unexpected, and the psychological effects consequently may be stronger. Further, iatrogenic 
problems (ocular irritation, visual disturbances and pain) frequently emerge several years after 
treatment.23,24  
Second, FCR is based in subjective appraisals that may not reflect objective 
vulnerability. In interpreting paths related to FCR, it is important to understand the extent to 
which FCR is objectively grounded. If FCR is independent of vulnerability,14 interventions 
should aim to address patients’ tendencies toward worry and any misperceived vulnerability.15 
However, if worry derives from objective vulnerability, the therapeutic goal becomes helping 
high-risk individuals to tolerate it.25 Studies note the invariance of FCR between groups with 
different objective risk profiles,14, 26 but relationships between worry and objective risk cannot 
be directly examined between individuals because objective recurrence risks are difficult to 
estimate.14 A UM population allows us to overcome this problem. Unlike other cancers, UM 
recurrence risk can be predicted with sufficient accuracy to provide survivors with reliable life 
expectancy estimates.22 40-50% of survivors will develop metastatic disease within 10 years, 
for which treatment rarely prolongs life. This risk can be measured and life expectancy 
estimated.22 Patients in our sample were offered prognostic testing and informed of prognoses. 
Statistical control of prognoses exposes worry of metastatic death that is based on inaccurately 
high risk perceptions.  
Study Objectives 
Our aim was to prospectively examine pathways between physical symptoms and 
functional problems, FCR and anxiety and depression in UM survivors. We used a cross-
lagged, five-year, six-observation design to examine potential paths. The objective was to test 
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three paths: 1) direct paths - concerns about physical symptoms, functional problems and FCR 
uniquely predict anxiety and depression at the next observation; 2) indirect paths - physical 
symptoms and functional  problems predict FCR at the next observation, which in turn predicts 
later anxiety and depression; and 3) reciprocal paths - anxiety and depression predict physical 
symptoms, functional problems and FCR, which predict anxiety and depression at the next 




Participants and Procedure  
The study was approved by the Health Research Authority NorthWest – Liverpool 
Central Ethics Committee (03/06/072/A) in accordance with the Declaration of Helsinki 2006. 
The sampling frame was a consecutive series of adult patients from England or Wales treated 
for posterior UM (i.e., choroid and ciliary body) between April 1st 2008 and December 31st 
2014 at the Liverpool Ocular Oncology Centre (LOOC), one of the largest tertiary referral 
centres in the United Kingdom.  Cross-lagged designs typically show small effect sizes due to 
autoregressive effects. A priori power analysis showed a sample size of 476 necessary to detect 
a very small effect size of .02 (alpha=.05, power=.080). Diagnosis and treatment of UM was 
based on clinical and tumour characteristics described by Damato and Heimann.27 Most 
patients had ruthenium plaque radiotherapy or proton beam radiotherapy. If the tumour was 
unsuitable for radiotherapy, because of its location or size, patients underwent trans-scleral 
local resection, trans-retinal endoresection or enucleation (i.e., amputation) of the affected eye. 
Patients were also offered prognostic testing if tumour biopsy was feasible. Patients who 
consented to prognostic testing received an explanation of their results from either a member 
of LOOC or a member of their clinical oncology team.  
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At diagnosis, all patients were asked if they were willing to participate in an audit to 
examine patient reported treatment outcomes. Patients who gave written consent were posted 
questionnaires at six observation points (6-, 12-, 24-, 36-, 48- and 60-months after diagnosis) 
with enclosed postage-paid envelopes. Surgical and radiographic treatments and 
communication of prognostic test results were completed before the initial 6-month 
observation. To examine long-term survivorship whilst minimising error in missing data 
estimation, patients were included if they contributed data at the 6-month observation and did 
not miss two consecutive observations after that point.  
Measures 
Demographic, clinical and treatment variables were collected from clinical records. 
These included age, gender, relationship and employment status, vision quality (visual acuity 
measured by logMar values converted from Snellen test scores28 in the unaffected eye at 
diagnosis), tumour origin (choroid or ciliary body) and primary treatment type including 
whether the affected eye was conserved or removed (enucleation). Metastatic disease develops 
almost exclusively in patients whose tumour shows deletion of one of the normal two copies 
of chromosome 3 (monosomy 3 (M3); disomy 3 is normal maternal and paternal copies of 
chromosome 3).22 For the present analysis, outcomes of testing were categorized as: M3 and 
disomy 3 and unknown (comprising patients who did not wish to be tested, where tumour 
characteristics did not suggest likely M3, and those whose genetic test failed).  
Anxiety and depression symptoms were measured using the subscales of the Hospital 
Anxiety and Depression Scale (HADS),29 which predicts anxiety and depression diagnoses.30 
Participants rate the extent to which they have experienced common symptoms of anxiety (7 
items) and depression (7 items) in the preceding week using a 4-point Likert scale. Items are 
summed to give scores for anxiety and depression (range 0-21 for each); higher scores indicate 
greater anxious and depressive symptomatology, respectively.  
Post-treatment symptoms and functional problems were measured using the European 
Organisation for Research and Treatment for Cancer Ophthalmic Quality of Life questionnaire 
This article is protected by copyright. All rights reserved.
ANXIETY AND DEPRESSION IN UVEAL MELANOMA 
 
  
(EORTC OPT 30),31 designed for UM patients and validated in UM samples.32 Subscales or 
items pertaining only to subsamples, such as having received enucleation treatment or problems 
with driving, were not used. Subscales used in this study were: ocular irritation (e.g., discharge 
from the eye), a 6-item scale with Cronbach alphas in the current sample of .71 at 6 months 
and .75 at 12 months; vision impairment (e.g., troubled by any defects in side vision), a 4-item 
scale with alpha of .69 at 6-months and .73 at 12; a single item measuring headache (‘Did you 
have headaches?’), functional problems (e.g., ‘Difficulty seeing steps or pavements?’), 
difficulty reading and concerns about appearance. Response format for all EORTC OPT 30 items 
is ‘Not at all’, ‘A little’, ‘Quite a bit’ and ‘Very much’, scored 1-4, respectively. Higher scores 
indicate poorer outcomes. To simplify analysis, confirmatory factor analysis was used to test a 
single latent factor model consisting of the six subscales. A final single factor model showed 
satisfactory fit, Χ2(2.65) =15.87, CFI=.98, RMSEA=.06. The six scales were reduced to a single 
mean of the six.  
The EORTC OPT 30 has a 4-item scale for worry about recurrence (WREC). This study 
was designed before much of the FCR literature and its measures emerged. On the basis of item 
similarity with current FCR scales, we argue that the WREC scale appropriately assesses FCR. 
Three items were used, with an alpha of .87 at 6 months and .85 at 12 months: ‘Were you 
worried about your health in the future?’; ‘Were you worried about the tumour recurring in the 
treated eye?’ and ‘Were you worried about the tumour recurring in other areas of your body?’ 
An item on concern about loss of the eye was excluded because it was irrelevant to enucleated 
patients.  Response format for all EORTC OPT 30 items is ‘Not at all’, ‘A little’, ‘Quite a bit’ 
and ‘Very much’, scored 1-4, respectively. Higher scores indicate higher concerns.  
Statistical Methods 
Cross-lagged analyses were performed using structural equation modelling in Amos 24. 
Cross-lagged analyses examine prospective relationships between variables whilst controlling 
autocorrelation. Key events can be temporally located (for example, in a 6-, 12-, and 24-month 
observation design, prediction of a 24-month variable by a 12-month variable means that a 12- 
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to 24-month change in the outcome was caused by an earlier 6- to 12-month change in the 
predictor) but cause not fully proven.  
Separate analyses were conducted for anxiety and depression. Cross-lagged predictor 
variables were concerns about physical symptoms and functional problems, WREC and anxiety 
or depression. Age, gender, treatment modality, visual acuity of the fellow eye, whether 
survivors were M3 or not (of which survivors are informed before the 6-month observation 
point) were initially used as covariates. Maximum likelihood estimation was made using 
unbiased covariances. Goodness of model fit was assessed by CMIN, CFI and RMSEA. 
Missing data were replaced using full information maximum likelihood estimation. Predictive 
paths were identified by noting sequences in significant cross-paths (e.g., a reciprocal path 
might be 6-month physical problems predicting 12-month anxiety, which then predicts 24-
month physical problems).  
Bias in retention was assessed using multivariate logistic regression to predict the 453 
survivors who met inclusion criteria from characteristics of the 814 who provided data at 6-
months. Predictors were age sex, treatment type (enucleation, plaque radiotherapy, proton 
beam radiotherapy, resection or other), M3, and 6-month physical symptoms, functional 
problems, WREC, depression and anxiety. 
Results 
Of 1,471 patients approached, 55.4% (814) completed the 6-month observation. Of 
these 814, 773 contributed at 12 months (95.0%), 706 at 24 (86.7%), 619 at 36 (76.1%), 557 at 
48 (68.4%), and 438 at 60 (53.8%). The final sample was 453 patients (55.7% of 814), 240 
males (53.0%) and 213 females (47.0%) with mean age at treatment of 69.48 (SD=11.57). 
Table 1 shows participant characteristics.  
Table 2 shows means, SDs and temporal trends in study variables. Concerns mean item 
scores were midway between the item labels ‘not [concerning] at all’ and ‘a bit (concerning), 
WREC means of about 2.00 correspond to item label ‘quite a bit [concerning]’. Subscale means 
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were broadly similar to community norms. Anxiety and depression mean scores did not change 
over the five years, whilst concerns and WREC reduced. Correlations can be found in 
Appendix 1, and show positive associations, cross-sectionally and prospectively, between all 
variables. 
Cross-Lagged Model for Anxiety 
Treatment modality and visual acuity of the fellow eye did not improve models or 
predict any study variables. These were omitted from the reported model. Age, sex and M3 
status were used as covariates. The full-sample model for anxiety did not show good fit 
(CMIN(df=6.47)=879.23, CFI=.890, RMSEA=.083).33 A multigroup model based on gender 
showed better fit (CMIN(df=350)=1259.95, CFI=.885, RMSEA=.076), and significant 
differences in structural relationships between male and female analyses (CMIN=90.14 
(df=51), p<.001). Figure 1 shows significant structural relationships for each gender (see 
appendices 2 and 3 for full structural relationships).  
Younger survivors of both genders showed greater 6-month worry about recurrence and 
anxiety than older, and younger female survivors reported greater concerns. M3 survivors1 of 
both genders showed greater worry, suggesting that survivors’ 6-month worries were consistent 
with objective risk.  
Direct Paths: Concerns at 6 months predicted anxiety at 12 months in males only. As a 
pre-treatment baseline was not used, it is not clear whether 6-month concerns that emerged 
before or after treatment. Worry at 24 months also predicted 36-month anxiety. In females, 
WREC at 12 months predicted anxiety at 24. 
Indirect Paths: Males did not show indirect paths, but females showed two paths. 
Concerns at 6 months predicted 12-month worry, which then predicted anxiety at 24 months. 
36-month concerns predicted 48-month worry, which predicted 60-month anxiety.  
                                                 
1 We also assessed the effect of disomy 3 status on the model, finding, the opposite of M3 status, that disomy 3 
predicted less anxiety and depression without influencing the significance of other components of the structural 
model. 
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Reciprocal Paths: A single reciprocal path was found. In males, 12-month anxiety 
predicted 24-month worry, which then predicted 36-month anxiety.   
Cross-Lagged Model for Depression 
The same covariates were used as the anxiety analysis. Again, better fit was obtained 
for a multigroup gender model (CMIN(240) =1065, CFI=.955, RMSEA=.077; full sample model 
Χ2(6.72) =713.71, CFI=.88, RMSEA=.11) with significant structural differences between males 
and females (CMIN=93.62 (df=51) p<.001). Figure 2 shows structural relationships (see 
appendices 2 and 3 for full relationships). M3 survivors of both genders showed greater worry, 
and female M3 survivors showed higher depression scores at 12 months. Younger survivors of 
both genders showed higher 6-month worry and female younger survivors showed higher 
concerns and depression. 
Direct Paths: For both genders, 24-month concerns predicted 36-month depression, and 
36-month concerns predicted 48-month depression. In females, 24-month FCR predicted 36-
month depression, and 36-month WREC predicted 48-month depression 
Indirect Paths: There were no indirect paths.  
Reciprocal Paths: In males, 12-month depression predicted 24-month concerns which 
predicted 36-month depression. In females, 24-month depression predicted 36-month concerns 
which predicted 48-month depression.    
Retention Analysis 
Binary logistic regression, using all 6-month variables as predictors, showed a 
multivariate difference between the 453 retained and non-retained participants in the 6-month 
observations (chi-sq=18.82, df=9, Nagelkerke R2=.10, p<.05). Not being M3 positive predicted 
retention (odds ratio=1.92, lower 95% C.I.=1.24, upper 95% C.I.= 2.96). Half (112; 46.1%) of 
M3 positive survivors were retained. Ten died during the study. Three hundred and forty-one 
(59.7%) disomy 3 survivors were retained. Seven died during the course of the study. 
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We found some evidence for our predicted paths. Concerns over physical symptoms 
and functional difficulties and worry directly predicted subsequent anxiety and depression. 
WREC mediated2 an indirect path between concerns and anxiety and depression in females. In 
reciprocal paths, anxiety and depression predicted concerns, which in turn predicted anxiety 
and depression. Path initiation frequently post-dated completion of primary treatment, 
suggesting that symptoms, functional problems and worry arising during survivorship may 
cause anxiety and depression.  
Findings extend cross-sectional2,4,12,14 and prospective17 evidence. Specific conclusions 
can now be drawn about time-frames within which effects occurred. In particular, we suggest 
that anxiety and depression are consequences of the dynamic process of how patients’ concerns 
and worries develop and remit during survival, not mere consequences of diagnosis or 
treatment. Second, the temporal sequence of prediction provides the strongest support yet for 
a causal argument, although spurious effects from unmeasured variables are possible.  
We did not investigate mechanisms underpinning paths, but we advance plausible 
hypotheses. Effects of symptoms, such as pain, and functional limitation on anxiety and 
depression, are well documented in the cancer and wider literature.34,35 Perceived physical 
symptoms may increase the salience of survivors’ negative memories and thoughts about their 
illnesses.16 In particular, visual disturbances and physical sensations in and around the eye, 
measured by the EORTC OPT 30, could evoke traumatic memories of diagnosis or treatment.  
Research is needed to elucidate mediators and moderators of relationships between concerns 
about physical symptoms and functional problems and anxiety and depression. 
 Worry about recurrence, the scale we used to operationalise FRC, may mediate effects 
of concerns on anxiety.17 As emphasised in several studies,14, 16, 26 physical symptoms and 
functional problems cause FCR. We speculate that perceived physical symptoms, particularly 
                                                 
2 Unmeasured variables may create spurious effects. Thus, true causal mediation cannot be proved. For brevity, 
the term ‘mediation’ is used, but this limitation should be borne in mind.  
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in and around the eye, might be either mistaken for cancer or cause worry by reminding 
survivors of cancer experiences.15 M3 positive status predicted higher worry scores, suggesting 
that FCR is partly based in objective risk. However, changes in concerns predicted worry after 
M3 status was known, suggesting that indirect paths were largely independent of prognosis. 
Non-mediation of depression by worry may not be surprising in the light of a distinction 
between both worry and anxiety as deriving from future-oriented cognitions, associated with 
the prospect of loss or harm, such as cancer recurrence, whereas depression is rooted in 
experiences of past loss.36  
Reciprocal paths suggest that anxiety and depression cause concerns about physical 
symptoms or functional problems, potentially worsening the initial anxiety or depression. This 
could enmesh survivors in a spiral of increasing anxiety and depression. There are two reasons 
that anxiety and depression might increase concerns or FCR. Anxiety and depression are risk 
factors for cancer symptom progression. This may be biologically mediated.37 From a 
psychological perspective, negative interpretive biases associated with anxiety and depression 
could cause survivors to adversely interpret their existing symptoms and functional 
limitations.20 If so, even sub-clinical levels of anxiety and depression might require 
intervention to prevent future deterioration.  
Structural models differed for males and females. Paths were broadly similar across 
genders, but occurred at different observations. Indirect prediction of FCR was limited to 
females. Females had higher FCR scores, and it may be that worry about recurrence is more 
likely to be activated in females than males,38 and consequently more likely to activate anxiety.   
Study limitations 
Generalisation to other cancers must be made carefully. We particularly note the 
relatively low concerns survivors expressed, and mean anxiety and depression scores that were 
not greater than those of age-matched healthy populations.3 Cancers associated with higher 
concerns and HADS scores, might show differing structural relationships. The retention rate of 
54% over five years is reasonable and we found little retention bias, but 55% of eligible patients 
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did not enter this study. Non-participants’ characteristics may differ from participants’,23,24 and 
we do not know how non-participation affected findings. Effect sizes were small, but cross-
lagged models provide conservative estimates when temporal stability is high.39 We observed 
large stability coefficients, and structural coefficients that were typically smaller than their 
corresponding univariate correlations. Thus, effects may be larger than cross-lagged models 
suggest. Our objective was to examine predictors of symptomology in a large sample of UM 
survivors. We did not apply psychiatric inclusion or exclusion criteria. Thus, findings should 
not be interpreted in terms of predictors of diagnosed cases. Also, we did not collect data 
pertaining to psychological or pharmacological treatments. Where cases are successfully 
treated, this will probably lead to attenuation of relationships between predictor and outcome 
variables.  
Clinical implications 
Most paths originated during survivorship, but medical, social and psychological 
support for patients focusses on diagnosis and treatment, rather than survivorship.40 A key 
study outcome is identifying risk factors for anxiety and depression through survivors’ 
concerns about physical symptoms, functional problems and FCR. Reciprocal effects suggest 
that even sub-clinical anxiety or depression  constitute potential risk factors.  
One recommendation is to develop programmes that monitor survivors’ anxiety, 
depression, concerns about physical symptoms and functional problems and FCR. Part of 
prevention will involve alleviating post-treatment medical problems, although many are not 
easily treated. Thus, education programmes are important to help survivors to anticipate and 
understand the implications of symptoms and functional problems, particularly in relation to 
FCR. Where perceptions of symptoms, functional limitations and recurrence risk are 
unrealistic, accurate information may help. Where these are objectively problematic, 
programmes based in coping, metacognitive, mindfulness and acceptance and commitment 
approaches might help survivors to meet challenges.25  
Conclusions 
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New interventions will need to be underpinned by research that develops better 
understandings of why survivors’ concerns about symptoms and functional problems render 
them directly vulnerable to worry about anxiety and depression, and indirectly vulnerable 
through FCR.  
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Table 1: Participant Characteristics 
Table 2: Means and Standard Deviations of Study Measures and Analysis of Temporal Trends 
Figure 1: Cross-Lagged Analysis Showing Significant Structural Relationships Between 
Predictors and Anxiety for Males (M) and Females (F). Bold Arrows Indicate Significant Paths 
for One or Both Genders. Full Structural Coefficients for Both Genders are in Appendix 2. 
Figure 2: Cross-Lagged Analysis Showing Significant Structural Relationships Between 
Predictors and Depression for Males (M) and Females (F). Bold Arrows Indicate Significant 
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Table 1: Participant Characteristics 




Relationship Status Relationship 348 76.8% 
 Divorce/Separate 27 6.0% 
 Widowed 48 10.6% 
 Single 29 6.4% 
Employment Status Employed 171 37.7% 
 Homemaker 16 3.5% 
 Retired 221 48.8% 
 Unemployed 8 1.8% 
 Sickness leave 17 3.8% 
 Student 14 3.1% 
 Unknown 6 1.3% 
Affected Eye Left 222 49.0% 
 Right 231 51.0% 
Visual acuity* (Affected eye)  1.22 0.27 
Visual acuity (Unffected eye)  1.43 0.28 
Chromosome 3 Status Monosomy 3 118 26.0% 
 Disomy 3 135 29.8% 
 Did not accept test 164 36.2% 
 Biopsy failed 36 8.0% 
Treatment Plaque radiotherapy 219 48.3% 
 Proton beam radiotherapy 99 21.9% 
 Enucleation 92 20.3% 
 Resection 26 5.7% 
 Other 17 3.8% 
* Visual acuity is presented in the logmar scale (converted from Snellen scores). Scores of zero 
indicating good vision, negative values better vision and positive values worse vision.  
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** This includes patients who were not offered tests, who refused tests or testing failed. 
Note: SD = standard deviation 
 
 
Table 2: Means and Standard Deviations of Study Measures and Analysis of Temporal Trends 
  Anxiety Depression Concerns 
Worry About 
Recurrence 
 Mean SD Mean SD Mean SD Mean SD 
6 months 5.12 4.01 2.93 3.09 1.53 0.43 2.34 0.88 
12 months 4.83 4.03 2.99 3.21 1.51 0.43 2.10 0.79 
24 months 4.86 3.86 2.90 3.15 1.49 0.43 2.04 0.75 
36 months 4.90 4.09 3.09 3.51 1.49 0.42 1.95 0.74 
48 months 4.86 4.07 3.19 3.27 1.46 0.41 1.98 0.75 










Note: SD = standard deviation 
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